340 related articles for article (PubMed ID: 32014010)
1. Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment.
Botticelli A; Vernocchi P; Marini F; Quagliariello A; Cerbelli B; Reddel S; Del Chierico F; Di Pietro F; Giusti R; Tomassini A; Giampaoli O; Miccheli A; Zizzari IG; Nuti M; Putignani L; Marchetti P
J Transl Med; 2020 Feb; 18(1):49. PubMed ID: 32014010
[TBL] [Abstract][Full Text] [Related]
2. Network Analysis of Gut Microbiome and Metabolome to Discover Microbiota-Linked Biomarkers in Patients Affected by Non-Small Cell Lung Cancer.
Vernocchi P; Gili T; Conte F; Del Chierico F; Conta G; Miccheli A; Botticelli A; Paci P; Caldarelli G; Nuti M; Marchetti P; Putignani L
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33227982
[TBL] [Abstract][Full Text] [Related]
3. Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancer.
Luo WC; Mei SQ; Huang ZJ; Chen ZH; Zhang YC; Yang MY; Liu JQ; Xu JY; Yang XR; Zhong RW; Tang LB; Yin LX; Deng Y; Peng YL; Lu C; Chen BL; Ke DX; Tu HY; Yang JJ; Xu CR; Wu YL; Zhou Q
J Transl Med; 2024 Apr; 22(1):326. PubMed ID: 38566102
[TBL] [Abstract][Full Text] [Related]
4. Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients.
Song P; Yang D; Wang H; Cui X; Si X; Zhang X; Zhang L
Thorac Cancer; 2020 Jun; 11(6):1621-1632. PubMed ID: 32329229
[TBL] [Abstract][Full Text] [Related]
5. Gut microbiome affects the response to immunotherapy in non-small cell lung cancer.
Ren S; Feng L; Liu H; Mao Y; Yu Z
Thorac Cancer; 2024 May; 15(14):1149-1163. PubMed ID: 38572783
[TBL] [Abstract][Full Text] [Related]
6. Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non-small cell lung cancer.
Xin Y; Liu CG; Zang D; Chen J
Front Immunol; 2024; 15():1343450. PubMed ID: 38361936
[TBL] [Abstract][Full Text] [Related]
7. [Association between Immunotherapy with Immune Checkpoint Inhibitors(Anti-PD-1 Antibodies)and Intestinal Microbiota].
Ozaki Y; Suzuki Y; Nishiyama K; Suzutani T; Suzuki H
Gan To Kagaku Ryoho; 2021 Sep; 48(9):1096-1099. PubMed ID: 34521783
[TBL] [Abstract][Full Text] [Related]
8. Chronological analysis of the gut microbiome for efficacy of atezolizumab-based immunotherapy in non-small cell lung cancer: Protocol for a multicenter prospective observational study.
Shoji F; Miura N; Tagawa T; Tsukamoto S; Okamoto T; Yamazaki K; Hamatake M; Takeo S
Thorac Cancer; 2022 Oct; 13(19):2829-2833. PubMed ID: 36063818
[TBL] [Abstract][Full Text] [Related]
9. Association of Short-Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer Tumors.
Nomura M; Nagatomo R; Doi K; Shimizu J; Baba K; Saito T; Matsumoto S; Inoue K; Muto M
JAMA Netw Open; 2020 Apr; 3(4):e202895. PubMed ID: 32297948
[TBL] [Abstract][Full Text] [Related]
10. Unveiling the altered metabolic pathways induced by nivolumab in non-small cell lung cancer via GC-MS metabolomics approach coupled with multivariate analysis.
Alosaimi ME; Alotaibi BS; Abduljabbar MH; Alnemari RM; Almalki AH; Serag A
J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Jun; 1240():124144. PubMed ID: 38703714
[TBL] [Abstract][Full Text] [Related]
11. Gut microbiome and response to checkpoint inhibitors in non-small cell lung cancer-A review.
Nagasaka M; Sexton R; Alhasan R; Rahman S; Azmi AS; Sukari A
Crit Rev Oncol Hematol; 2020 Jan; 145():102841. PubMed ID: 31884204
[TBL] [Abstract][Full Text] [Related]
12. Unbiased Microbiome and Metabolomic Profiling of Fecal Samples from Patients with Melanoma.
Bui A; Choi Y; Frankel AE; Koh AY
Methods Mol Biol; 2021; 2265():461-474. PubMed ID: 33704734
[TBL] [Abstract][Full Text] [Related]
13. Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy.
Passaro A; Mancuso P; Gandini S; Spitaleri G; Labanca V; Guerini-Rocco E; Barberis M; Catania C; Del Signore E; de Marinis F; Bertolini F
Clin Transl Oncol; 2020 Apr; 22(4):603-611. PubMed ID: 31254252
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review.
Ding H; Xin W; Tong Y; Sun J; Xu G; Ye Z; Rao Y
PLoS One; 2020; 15(9):e0238536. PubMed ID: 32877435
[TBL] [Abstract][Full Text] [Related]
16. Combined analysis of gut microbiome and serum metabolomics reveals novel biomarkers in patients with early-stage non-small cell lung cancer.
Ni B; Kong X; Yan Y; Fu B; Zhou F; Xu S
Front Cell Infect Microbiol; 2023; 13():1091825. PubMed ID: 36743312
[TBL] [Abstract][Full Text] [Related]
17. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
[TBL] [Abstract][Full Text] [Related]
18. Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer.
Katayama Y; Yamada T; Tanimura K; Yoshimura A; Takeda T; Chihara Y; Tamiya N; Kaneko Y; Uchino J; Takayama K
Thorac Cancer; 2019 Mar; 10(3):526-532. PubMed ID: 30666802
[TBL] [Abstract][Full Text] [Related]
19. Cancer immunotherapy resistance: The impact of microbiome-derived short-chain fatty acids and other emerging metabolites.
Hersi F; Elgendy SM; Al Shamma SA; Altell RT; Sadiek O; Omar HA
Life Sci; 2022 Jul; 300():120573. PubMed ID: 35469916
[TBL] [Abstract][Full Text] [Related]
20. Alterations in the Gut Microbiome and Cecal Metabolome During
Wu T; Xu F; Su C; Li H; Lv N; Liu Y; Gao Y; Lan Y; Li J
Front Immunol; 2020; 11():1331. PubMed ID: 32849494
[No Abstract] [Full Text] [Related]
[Next] [New Search]
